Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast ...

fueling colorectal cancer. Its findings pave the way ... Dec. 9, 2024 — Oral minoxidil is a commonly prescribed treatment for hair loss. The drug is also the active ingredient in over-the ...

Dec. 9, 2024 — Metastasis is responsible for 90 percent of cancer deaths. Researchers have found that the mutations driving it may stem from a commonly inherited variant of the PCSK9 ...

The global AI in medical diagnostics market is likely to grow from USD 1.71 billion in 2024 to USD 4.72 billion by 2029, at a ...

After seeing the oral health of many of his older patients deteriorate drastically, dentist Johan Flyborg started looking for a solution.

Australian-led research is unlocking new ways for immunotherapy to better target cancer. Cancer immunotherapy has revolutionized treatment for patients, whereby the body's own immune system is ...

Irving, Texas-based U.S. Oral Surgery Management is preparing for a more favorable business climate in 2025 after dealing with several challenges that faced the dental industry this year. USOSM is a ...

Finding an equitable solution? As Mercury and Venus harmonize, a rational compromise presents itself. Everyone gets to win. Over the past two days, fear got the better of you. You tried to achieve ...